Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Clinical Trial Evaluating the Benefits of Doxorubicin Chemoembolization Versus Systemic Doxorubicin in Patients With Unresectable, Advanced Hepatocellular Carcinoma

NCT00079027 is registered in ClinicalTrials.gov with University Hospital Birmingham as lead sponsor.

NCT NCT00079027
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00079027 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Clinical Trial Evaluating the Benefits of Doxorubicin Chemoembolization Versus Systemic Doxorubicin in Patients With Unresectable, Advanced Hepatocellular Carcinoma
Lead sponsor
University Hospital Birmingham
Phase
Phase 3
Overall status
Unknown status
Start date
April 30, 2004
Completion date
Not reported
Enrollment
280 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

liver cancer